including the United States," GSK said in its report. Rival UK drugmaker AstraZeneca said in its annual report published last week that it remained committed to its diversity and inclusion targets.

To properly understand GSK's profit results, we need to consider the UK£2.2b expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there ...

“There needs to be material progress on the pipeline or successful M&A to help address the chronic long-term underperformance of the share price,” said Ketan Patel, fund manager at the family office .

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

The FDA approved GSK’s meningococcal vaccine for children and young adults aged 10 to 25 years, according to a press release. Image: Adobe Stock. According to the release, serogroup B is the ...

Spring isn’t fully here yet, but it could be on its way (Picture: Shutterstock) After last week’s long term Met Office forecast predicted the UK could see a slight reprieve in early March from ...

Last year, in total, the company distributed UK£0.61 to shareholders. Based on the last year's worth of payments, GSK stock has a trailing yield of around 4.3% on the current share price of UK£ ...